TABLE 2.

Univariate analysis of clinical prognostic factors for clinical outcomes in 49 HNSCC patients

Variable	OS			PFS
	HR	95% CI	p	HR	95% CI	p
BMI at diagnosis			0.001			0.002
Normal	Ref.
Underweight	5.131	1.959–13.443	0.001	4.690	1.776–12.385	0.002
Overweight	0.181	0.024–1.391	0.100	0.194	0.025–1.479	0.114
Obese	0.438	0.056–3.401	0.430	0.489	0.064–3.737	0.491
Gender (vs. Female)	0.612	0.259–1.448	0.264	0.652	0.276–1.540	0.329
Age (vs.<60 years)	1.212	0.535–2.748	0.645	1.091	0.481–2.473	0.835
Prior treatment (vs. cetuximab)	2.739	1.013–7.410	0.047	3.280	1.205–8.931	0.020
Radiotherapy (vs. No)	0.635	0.261–1.546	0.317	0.535	0.219–1.307	0.170
Serum albumin level	0.945	0.861–1.037	0.230	0.940	0.857–1.031	0.191
ECOG‐PS(vs. ≥2)	0.168	0.068–0.412	<0.001	0.153	0.062–0.376	<0.001
CPS(vs. ≥1)	5.398	1.995–14.903	0.001	5.306	1.946–14.471	0.001
rT‐stage (vs. T3)	4.414	1.627–11.976	0.004	3.998	1.474–10.840	0.006
Tube feeding (vs. No)	1.342	0.587–3.071	0.486	1.404	0.614–3.208	0.421

Note: Underweight (BMI <18.5 kg/m²), Normal (18.5 ≤BMI <23.5 kg/m²), Overweight (23.5 ≤BMI <27.5 kg/m²), and Obese (BMI ≥27.5 kg/m²). OS, overall survival; PFS, progression‐free survival; CTX, cetuximab. CI, confidence interval; HR, hazard ratio; Ref, reference (HR = 1.0). Boldface indicates p < 0.05.